Revenue ₹15,469 Cr (+15.1% YoY)
Healthcare
Tracked since Q1 FY24 - Q3 FY26
Sunpharma Ltd
SUNPHARMA
0 met · 1 close · 17 missed across 18 tracked promises
View all executive profiles for Sunpharma LtdSun Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 15,469 crore (+15.1% YoY) and EBITDA of INR 4,...
0% promises delivered
Based on 18 tracked promises across 11 quarters
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q3 FY26
07 Feb 2026
Revenue ₹15,469 Cr (+15.1% YoY)
Sun Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 15,469 crore (+15.1% YoY) and EBITDA of INR 4,949 crore (+23.4% YoY), driven by broad-based grow...
bullish
high
3 missed
Read full analysis →
Q2 FY26
14 Nov 2025
Revenue ₹14,405 Cr (+8.6% YoY)
Sun Pharma reported a solid Q2 FY26 with consolidated revenue of INR 14,405 crore (+8.6% YoY) and EBITDA of INR 4,527 crore (+14.9% YoY), with EBITDA margin expanding...
bullish
medium
1 missed
Read full analysis →
Q1 FY26
01 Aug 2025
Revenue ₹13,786 Cr (+10.1% YoY)
Sun Pharma reported Q1 FY26 consolidated revenue of INR 13,786 crore, up 10.1% YoY, driven by India formulation growth of 13.9% and global Innovative Medicines growth...
bullish
medium
1 missed
Read full analysis →
Q4 FY25
15 May 2025
Revenue ₹12,816 Cr (+8.5% YoY)
Sun Pharma reported Q4 FY25 consolidated revenue of INR 12,816 crore, up 8.5% YoY, with EBITDA of INR 3,716 crore (+22.4% YoY) and margin expansion of 340 bps to 28.7%.
neutral
medium
2 missed
Read full analysis →
Q3 FY25
13 Feb 2025
Revenue ₹13,437 Cr (+10.5% YoY)
Sun Pharma delivered a solid Q3 FY25 with consolidated sales of INR 13,437 crore, up 10.5% YoY, driven by strong India (13.8% growth) and emerging markets (10.1% growth).
bullish
high
1 missed
Read full analysis →
Q2 FY25
14 Nov 2024
Revenue ₹13,264 Cr (+10.5% YoY)
Sun Pharma delivered a strong Q2 FY25 with consolidated sales of INR 13,264 crore, up 10.5% YoY, driven by US specialty growth (+20.3% to $517M) and India formulation...
bullish
high
2 missed
Read full analysis →
Q1 FY25
01 Aug 2024
Revenue ₹12,525 Cr (+6.3% YoY)
Sun Pharma reported a solid Q1 FY25 with consolidated sales of INR 12,524.5 crore (+6.3% YoY) and EBITDA margin expansion of 60 bps to 28.5%.
bullish
high
2 missed
Read full analysis →
Q4 FY24
15 May 2024
Revenue ₹11,813 Cr (+10.1% YoY)
Sun Pharma reported Q4 FY24 consolidated revenue of INR 11,813 crore, up 10.1% YoY, driven by strong specialty sales (Ilumya up 21.7% to $580M globally) and India form...
neutral
medium
1 close, 1 missed
Read full analysis →
Q3 FY24
23 Jan 2024
Revenue ₹12,157 Cr (+9.5% YoY)
Sun Pharma reported Q3 FY24 consolidated revenue of INR 12,157 crore, up 9.5% YoY, driven by strong specialty sales (up 26.1% to $296M) and India formulation growth of...
bullish
medium
1 missed
Read full analysis →
Q2 FY24
15 Nov 2023
Revenue ₹12,003 Cr (+11% YoY)
Sun Pharma reported Q2 FY24 consolidated revenue of INR 12,003 crore, up 11% YoY, driven by India formulations (11.1% growth) and global specialty sales (19.3% growth...
neutral
medium
3 missed
Read full analysis →
Q1 FY24
10 Aug 2023
Revenue ₹11,785 Cr (+10.7% YoY)
Sun Pharma reported Q1 FY24 consolidated revenue of INR 11,785 crore, up 10.7% YoY, driven by US specialty growth (up 21% to $232M) and episodic lenalidomide sales.
neutral
medium
Scorecard starts after historical backfill
Read full analysis →